Federal Register / Vol. 62, No. 150 / Tuesday, August 5, 1997 / Notices 42135

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

This notice is being published less than 15

days period to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.855, Immunology, Allergic

and Immunologic Diseases Research; 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health)

Dated: July 29, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–20551 Filed 8–4–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

National Institute of Child Health and

Human Development Special Emphasis

Panel (SEP) meeting:

Name of SEP: Outgoing of Perinatal Host

Defenses.

Date: August 7–8, 1997.

Time: August 7—7:00 p.m.–10:00 p.m.,

August 8—8:00 a.m.–adjournment.

Place: Betheda Marriott, 5151 Pooks Hill

Road Bethesda, Maryland 20814.

Contact Person: Edgar Hanna, Ph.D.,

Scientific Review Administrator, DSR, 6100

Executive Boulevard, Room 5E01, Bethesda,

Maryland 20892, Telephone: 301–496–1485.

Purpose/Agenda: To evaluate and review

research grant applications.

This meeting will be closed in accordance

with the provisions set forth in sections

552(b)(4) and 552b(c)(6), Title 5 U.S.C. The

discussion of these applications could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the applications, the

disclosure of which would constitute a

clearly unwarranted invasion of personal

privacy.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Nos. [93.846, Project Grants in

Arthritis, Muscloskeletal and Skin Diseases

Research], National Institutes of Health,

HHS)

Dated: July 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–20552 Filed 8–4–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and

Human Development; Notice of Closed

Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 United States Code

Appendix 2), notice is hereby given of

the following National Institute of Child

Health and Human Development

Special Emphasis Panel (SEP) meeting:

Name of SEP: Small Grant Review

(Teleconference).

Date: August 12, 1997.

Time: 2:00 p.m.–adjournment.

Place: 6100 Executive Boulevard, 6100

Building—Room 5E01, Bethesda, Maryland

20892.

Contact Person: Gopal M. Bhatnagar, Ph.D.,

Scientific Review Administrator, 6100

Executive Boulevard, 6100 Building—Room

5E01, Bethesda, Maryland 20892, Telephone:

301–496–1696.

Purpose/Agenda: To evaluate and review a

grant application.

The meeting will be closed in accordance

with the provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C. The

discussions of this application could reveal

confidential trade secrets or commercial

property such as patentable material and

personal information concerning individuals

associated with the application, the

disclosure of which would constitute a

clearly unwarranted invasion of personal

privacy.

This notice is published less than 15 days

prior to the meeting due to the urgent need

to meet timing limitations imposed by the

review and funding cycle.

(Catalog of Federal Domestic Assistance

Program Nos. [No. 93.865, Research Mothers

and Children], National Institutes of Health)

Dated: July 30, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–20553 Filed 8–4–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Current List of Laboratories Which

Meet Minimum Standards To Engage in

Urine Drug Testing for Federal

Agencies, and Laboratories That Have

Withdrawn From the Program

AGENCY: Substance Abuse and Mental

Health Services Administration, HHS

(Formerly: National Institute on Drug

Abuse, ADAMHA, HHS).

ACTION: Notice.

SUMMARY: The Department of Health and

Human Services notifies Federal

agencies of the laboratories currently

certified to meet standards of Subpart C

of Mandatory Guidelines for Federal

Workplace Drug Testing Programs (59

FR 29916, 29925). A similar notice

listing all currently certified laboratories

will be published during the first week

of each month, and updated to include

laboratories which subsequently apply

for and complete the certification

process. If any listed laboratory’s

certification is totally suspended or

revoked, the laboratory will be omitted

from updated lists until such time as it

is restored to full certification under the

Guidelines.

If any laboratory has withdrawn from

the National Laboratory Certification

Program during the past month, it will

be identified as such at the end of the

current list of certified laboratories, and

will be omitted from the monthly listing

thereafter.

This Notice is now available on the

internet at the following website: http:/

/www.health.org

FOR FURTHER INFORMATION CONTACT: Mrs.

Giselle Hersh or Dr. Walter Vogl,

Division of Workplace Programs, Room

13A–54, 5600 Fishers Lane, Rockville,

Maryland 20857; Tel.: (301) 443–6014.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal

Workplace Drug Testing were developed

in accordance with Executive Order

12564 and section 503 of Pub. L. 100–

71. Subpart C of the Guidelines,

‘‘Certification of Laboratories Engaged

in Urine Drug Testing for Federal

Agencies,’’ sets strict standards which

laboratories must meet in order to

conduct urine drug testing for Federal

agencies. To become certified an

applicant laboratory must undergo three

rounds of performance testing plus an

on-site inspection. To maintain that

certification a laboratory must

participate in a quarterly performance
42136 Federal Register / Vol. 62, No. 150 / Tuesday, August 5, 1997 / Notices

testing program plus periodic, on-site

inspections.

Laboratories which claim to be in the

applicant stage of certification are not to

be considered as meeting the minimum

requirements expressed in the HHS

Guidelines. A laboratory must have its

letter of certification from SAMHSA,

HHS (formerly: HHS/NIDA) which

attests that it has met minimum

standards.

In accordance with Subpart C of the

Guidelines, the following laboratories

meet the minimum standards set forth

in the Guidelines:

ACL Laboratory, 8901 W. Lincoln Ave.,

West Allis, WI 53227, 414–328–7875,

(formerly: Bayshore Clinical

Laboratory)

Aegis Analytical Laboratories, Inc., 345

Hill Ave., Nashville, TN 37210, 615–

255–2400

Alabama Reference Laboratories, Inc.,

543 South Hull St., Montgomery, AL

36103, 800–541–4931 / 334–263–5745

American Medical Laboratories, Inc.,

14225 Newbrook Dr., Chantilly, VA

22021, 703–802–6900

Associated Pathologists Laboratories,

Inc., 4230 South Burnham Ave., Suite

250, Las Vegas, NV 89119–5412, 702–

733–7866 / 800–433–2750

Associated Regional and University

Pathologists, Inc. (ARUP), 500 Chipeta

Way, Salt Lake City, UT 84108, 801–

583–2787 / 800–242–2787

Baptist Medical Center—Toxicology

Laboratory, 9601 I–630, Exit 7, Little

Rock, AR 72205–7299, 501–202–2783,

(formerly: Forensic Toxicology

Laboratory Baptist Medical Center)

Cedars Medical Center, Department of

Pathology, 1400 Northwest 12th Ave.,

Miami, FL 33136, 305–325–5784

Centinela Hospital Airport Toxicology

Laboratory, 9601 S. Sepulveda Blvd.,

Los Angeles, CA 90045, 310–215–

6020

Clinical Reference Lab, 8433 Quivira

Rd., Lenexa, KS 66215–2802, 800–

445–6917

CompuChem Laboratories, Inc., 1904

Alexander Drive, Research Triangle

Park, NC 27709, 919–549–8263 / 800–

833–3984, (Formerly: CompuChem

Laboratories, Inc., A Subsidiary of

Roche Biomedical Laboratory, Roche

CompuChem Laboratories, Inc., A

Member of the Roche Group)

Cox Health Systems, Department of

Toxicology, 1423 North Jefferson

Ave., Springfield, MO 65802, 800–

876–3652 / 417–269–3093, (formerly:

Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening

Laboratory, Great Lakes, IL, P.O. Box

88–6819, Great Lakes, IL 60088–6819,

847–688–2045 / 847–688–4171

Diagnostic Services Inc., dba DSI, 4048

Evans Ave., Suite 301, Fort Myers, FL

33901, 941–418–1700 / 800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658,

2906 Julia Dr., Valdosta, GA 31604,

912–244–4468

DrugProof, Division of Dynacare/

Laboratory of Pathology, LLC, 1229

Madison St., Suite 500, Nordstrom

Medical Tower, Seattle, WA 98104,

800–898–0180 / 206–386–2672

(formerly: Laboratory of Pathology of

Seattle, Inc., DrugProof, Division of

Laboratory of Pathology of Seattle,

Inc.)

DrugScan, Inc., P.O. Box 2969, 1119

Mearns Rd., Warminster, PA 18974,

215–674–9310

ElSohly Laboratories, Inc., 5 Industrial

Park Dr., Oxford, MS 38655, 601–236–

2609

General Medical Laboratories, 36 South

Brooks St., Madison, WI 53715, 608–

267–6267

Harrison Laboratories, Inc., 9930 W.

Highway 80, Midland, TX 79706,

800–725–3784 / 915–563–3300

(formerly: Harrison & Associates

Forensic Laboratories)

Jewish Hospital of Cincinnati, Inc., 3200

Burnet Ave., Cincinnati, OH 45229,

513–569–2051

LabOne, Inc., 8915 Lenexa Dr., Overland

Park, Kansas 66214, 913–888–3927 /

800–728–4064 (formerly: Center for

Laboratory Services, a Division of

LabOne, Inc.)

Laboratory Corporation of America, 888

Willow St., Reno, NV 89502, 702–

334–3400 (formerly: Sierra Nevada

Laboratories, Inc.)

Laboratory Corporation of America

Holdings, 69 First Ave., Raritan, NJ

08869, 800–437–4986 (Formerly:

Roche Biomedical Laboratories, Inc.)

Laboratory Specialists, Inc., 1111

Newton St., Gretna, LA 70053, 504–

392–7961

Marshfield Laboratories, Forensic

Toxicology Laboratory, 1000 North

Oak Ave., Marshfield, WI 54449, 715–

389–3734 / 800–331–3734

MedExpress/National Laboratory

Center, 4022 Willow Lake Blvd.,

Memphis, TN 38118, 901–795–1515/

800–526–6339

Medical College Hospitals Toxicology

Laboratory, Department of Pathology,

3000 Arlington Ave., Toledo, OH

43614, 419–381–5213

Medlab Clinical Testing, Inc., 212

Cherry Lane, New Castle, DE 19720,

302–655–5227

MedTox Laboratories, Inc., 402 W.

County Rd. D, St. Paul, MN 55112,

800–832–3244 / 612–636–7466

Methodist Hospital of Indiana, Inc.,

Department of Pathology and

Laboratory Medicine, 1701 N. Senate

Blvd., Indianapolis, IN 46202, 317–

929–3587

Methodist Medical Center Toxicology

Laboratory, 221 N.E. Glen Oak Ave.,

Peoria, IL 61636, 800–752–1835 /

309–671–5199

MetroLab-Legacy Laboratory Services,

235 N. Graham St., Portland, OR

97227, 503–413–4512, 800–237–

7808(x4512)

Minneapolis Veterans Affairs Medical

Center, Forensic Toxicology

Laboratory, 1 Veterans Drive,

Minneapolis, Minnesota 55417, 612–

725–2088

National Toxicology Laboratories, Inc.,

1100 California Ave., Bakersfield, CA

93304, 805–322–4250

Northwest Toxicology, Inc., 1141 E.

3900 South, Salt Lake City, UT 84124,

800–322–3361

Oregon Medical Laboratories, P.O. Box

972, 722 East 11th Ave., Eugene, OR

97440–0972, 541–687–2134

Pathology Associates Medical

Laboratories, East 11604 Indiana,

Spokane, WA 99206, 509–926–2400 /

800–541–7891

PharmChem Laboratories, Inc., 1505–A

O’Brien Dr., Menlo Park, CA 94025,

415–328–6200 / 800–446–5177

PharmChem Laboratories, Inc., Texas

Division, 7606 Pebble Dr., Fort Worth,

TX 76118, 817–595–0294 (formerly:

Harris Medical Laboratory)

Physicians Reference Laboratory, 7800

West 110th St., Overland Park, KS

66210, 913–338–4070 / 800–821–3627

Poisonlab, Inc., 7272 Clairemont Mesa

Blvd., San Diego, CA 92111, 619–279–

2600 / 800–882–7272

Premier Analytical Laboratories, 15201

I–10 East, Suite 125, Channelview, TX

77530, 713–457–3784 / 800–888–4063

(formerly: Drug Labs of Texas)

Presbyterian Laboratory Services, 1851

East Third Street, Charlotte, NC

28204, 800–473–6640

Quest Diagnostics Incorporated, 4770

Regent Blvd., Irving, TX 75063, 800–

526–0947 / 972–916–3376 (formerly:

Damon Clinical Laboratories, Damon/

MetPath, CORNING Clinical

Laboratories)

Quest Diagnostics Incorporated, 875

Greentree Rd., 4 Parkway Ctr.,

Pittsburgh, PA 15220–3610, 800–574–

2474 / 412–920–7733 (formerly: MedChek Laboratories, Inc., Med-Chek/

Damon, MetPath Laboratories,

CORNING Clinical Laboratories)

Quest Diagnostics Incorporated, 4444

Giddings Road, Auburn Hills, MI

48326, 810–373–9120 (formerly:

HealthCare/Preferred Laboratories,

HealthCare/MetPath, CORNING

Clinical Laboratories)

Quest Diagnostics Incorporated, 1355

Mittel Blvd., Wood Dale, IL 60191,
Federal Register / Vol. 62, No. 150 / Tuesday, August 5, 1997 / Notices 42137

630–595–3888 (formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratories Inc.)

Quest Diagnostics Incorporated, 2320

Schuetz Rd., St. Louis, MO 63146,

800–288–7293 / 314–991–1311

(formerly: Metropolitan Reference

Laboratories, Inc., CORNING Clinical

Laboratories, South Central Division)

Quest Diagnostics Incorporated, One

Malcolm Ave., Teterboro, NJ 07608,

201–393–5590 (formerly: MetPath,

Inc., CORNING MetPath Clinical

Laboratories, CORNING Clinical

Laboratory)

Quest Diagnostics Incorporated,

National Center for Forensic Science,

1901 Sulphur Spring Rd., Baltimore,

MD 21227, 410–536–1485 (formerly:

Maryland Medical Laboratory, Inc.,

National Center for Forensic Science,

CORNING National Center for

Forensic Science)

Quest Diagnostics Incorporated, 7470

Mission Valley Rd., San Diego, CA

92108–4406, 800–446–4728 / 619–

686–3200 (formerly: Nichols Institute,

Nichols Institute Substance Abuse

Testing (NISAT), CORNING Nichols

Institute, CORNING Clinical

Laboratories)

Scientific Testing Laboratories, Inc., 463

Southlake Blvd., Richmond, VA

23236, 804–378–9130

Scott & White Drug Testing Laboratory,

600 S. 25th St., Temple, TX 76504,

800–749–3788

S.E.D. Medical Laboratories, 500 Walter

NE, Suite 500, Albuquerque, NM

87102, 505–727–8800 / 800–999-

LABS

SmithKline Beecham Clinical

Laboratories, 7600 Tyrone Ave., Van

Nuys, CA 91405, 818–989–2520 /

800–877–2520

SmithKline Beecham Clinical

Laboratories, 801 East Dixie Ave.,

Leesburg, FL 34748, 352–787–9006

(formerly: Doctors & Physicians

Laboratory)

SmithKline Beecham Clinical

Laboratories, 3175 Presidential Dr.,

Atlanta, GA 30340, 770–452–1590

(formerly: SmithKline Bio-Science

Laboratories)

SmithKline Beecham Clinical

Laboratories, 506 E. State Pkwy.,

Schaumburg, IL 60173, 847–447–4379

/ 800–447–4379 (formerly:

International Toxicology Laboratories)

SmithKline Beecham Clinical

Laboratories, 400 Egypt Rd.,

Norristown, PA 19403, 800–523–0289

/ 610–631–4600 (formerly:

SmithKline Bio-Science Laboratories)

SmithKline Beecham Clinical

Laboratories, 8000 Sovereign Row,

Dallas, TX 75247, 214–638–1301

(formerly: SmithKline Bio-Science

Laboratories)

South Bend Medical Foundation, Inc.,

530 N. Lafayette Blvd., South Bend,

IN 46601, 219–234–4176

Southwest Laboratories, 2727 W.

Baseline Rd., Suite 6, Tempe, AZ

85283, 602–438–8507

St. Anthony Hospital (Toxicology

Laboratory), P.O. Box 205, 1000 N.

Lee St., Oklahoma City, OK 73102,

405–272–7052

Toxicology & Drug Monitoring

Laboratory, University of Missouri

Hospital & Clinics, 2703 Clark Lane,

Suite B, Lower Level, Columbia, MO

65202, 573–882–1273

Toxicology Testing Service, Inc., 5426

N.W. 79th Ave., Miami, FL 33166,

305–593–2260

TOXWORX Laboratories, Inc., 6160

Variel Ave., Woodland Hills, CA

91367, 818–226–4373 / 800–966–2211

(formerly: Laboratory Specialists, Inc.;

Abused Drug Laboratories; MedTox

Bio-Analytical, a Division of MedTox

Laboratories, Inc.)

UNILAB, 18408 Oxnard St., Tarzana,

CA 91356, 800–492–0800 / 818–996–

7300 (formerly: MetWest-BPL

Toxicology Laboratory)

UTMB Pathology-Toxicology

Laboratory, University of Texas

Medical Branch, Clinical Chemistry

Division, 301 University Boulevard,

Room 5.158, Old John Sealy,

Galveston, Texas 77555–0551, 409–

772–3197

The Standards Council of Canada

(SCC) Laboratory Accreditation Program

for Substances of Abuse (LAPSA) has

been given deemed status by the

Department of Transportation. The SCC

has accredited the following Canadian

laboratory for the conduct of forensic

urine drug testing required by

Department of Transportation

regulations: MAXXAM Analytics Inc.,

5540 McAdam Rd., Mississauga, ON,

Canada L4Z 1P1, 905–890–2555

(formerly: NOVAMANN (Ontario) Inc.).

Richard Kopanda,

Executive Officer, Substance Abuse and

Mental Health Services Administration.

[FR Doc. 97–20499 Filed 8–4–97; 8:45 am]

BILLING CODE 4160–20–U

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Substance Abuse and Mental Health

Services Administration

Center for Substance Abuse

Prevention; Notice of Meeting

Pursuant to Pub. L. 92–463, notice is

hereby given of the meeting of the Drug

Testing Advisory Board of the SAMHSA

Center for Substance Abuse Prevention

in September 1997.

The two-day scientific meeting will be

to continue discussing alternative

specimens and technologies of drug

testing (i.e., hair, saliva, sweat, and noninstrument based-on-site tests) as they

apply to workplace drug testing

programs. The entire meeting is open to

the public; however, attendance by the

public will be limited to space available.

Therefore, it would be helpful if those

planning to attend would pre-register by

following Registration instructions

below. There will be a limited time for

public comment during the meeting. If

anyone needs special accommodations

for persons with disabilities please

notify the Contact listed below. Any

individual desiring to make a formal

comment should notify the Contact

person listed below before August 29.

The purpose of the meeting is: (1) To

review the proposed principles and

criteria associated with a forensic

workplace drug testing program that

were presented at the April 28–30, 1997,

DTAB meeting and determine if those

are the appropriate standards that any

drug testing program needs to satisfy; (2)

to review the information and scientific

studies presented or submitted by the

representatives of the alternative

specimens and technology industries

during and/or after the April 28–30

DTAB meeting, to determine their

strengths and weaknesses, what criteria

they satisfy, and what areas may need

improvement; and (3) to make

recommendations to assist these

alternative specimens and technologies

to satisfy the criteria.

An agenda for this meeting and a

roster of board members may be

obtained from: Ms. Giselle Hersh,

Division of Workplace Programs, Room

13A–54, 5600 Fishers Lane, Rockville,

MD 20857, Telephone (301) 443–6014.

Substantive program information may

be obtained from the contact whose

name and telephone number is listed

below.

Committee Name: Drug Testing Advisory

Board.

Meeting Date: September 9–10, 1997.

Place: Sheraton National Hotel, Columbia

Pike & Washington Blvd, Arlington, Virginia

22204, Phone: (800) 468–9090.

Open: September 9, 1997, 8:30 a.m.–5:00

p.m., September 10, 1997, 8:30 a.m.–4:00

p.m.

Registration: Pre-register by calling: (301)

443–6014 or by FAX: (301) 443–3031 for

individuals planning to attend: full name,

organization and telephone number or sign in

upon arrival; there is no registration fee.

Contact: Donna M. Bush, Ph.D., Executive

Secretary, Telephone: (301) 443–6014 and

FAX: (301) 443–3031.